A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas

Kaito, Satoshi; Kanemasa, Yusuke; Sasaki, Yuki; Okuya, Toshihiro; Yamaguchi, Tadatsugu; Funasaka, Chikako; Shimoyama, Tatsu; Omuro, Yasushi; Hishima, Tsunekazu; Maeda, Yoshiharu

doi:10.1007/s12185-017-2362-6

Cited by 8 publications

(16 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, patient follow-up duration influences NLR, as illustrated by the fact that the largest differences observed across patient prognostic groups occur within the first 12 months of follow-up (11). Beside confirming the baseline prognostic value of NLR, its early decrease following only one cycle of chemotherapy appears to be of good prognosis in multiple pathologies: (i) colorectal cancer (13, 14); (ii) mesothelioma; (iii) triple-negative breast cancer (15); (iv) docetaxel-treated patients bearing lung, prostate, head and neck or breast cancers (16); (v) advanced pancreatic adenocarcinoma; and (vi) in peripheral T-cell lymphomas (17).…”

Section: Circulating Neutrophils In Cancermentioning

confidence: 99%

Neutrophil Heterogeneity in Cancer: From Biology to Therapies

et al. 2019

View full text Add to dashboard Cite

Neutrophils have been extensively described in the pathophysiology of autoimmune and infectious diseases. Accumulating evidence also suggests the important role of neutrophils in cancer progression through their interaction with cancer and immune cells in blood and in the tumor microenvironment (TME). Most studies have described neutrophils as key drivers of cancer progression, due to their involvement in various tumor promoting functions including proliferation, aggressiveness, and dissemination, as well as in immune suppression. However, such studies were focusing on late-stages of tumorigenesis, in which chronic inflammation had already developed. The role of tumor-associated neutrophils (TANs) at early stages of tumor development remains poorly described, though recent findings indicate that early-stage TANs may display anti-tumor properties. Beyond their role at tumor site, evidence supported by NLR retrospective studies and functional analyses suggest that blood neutrophils could also actively contribute to tumorigenesis. Hence, it appears that the phenotype and functions of neutrophils vary greatly during tumor progression, highlighting their heterogeneity. The origin of pro- or anti-tumor neutrophils is generally believed to arise following a change in cell state, from resting to activated. Moreover, the fate of neutrophils may also involve distinct differentiation programs yielding various subsets of pro or anti-tumor neutrophils. In this review, we will discuss the current knowledge on neutrophils heterogeneity across different tissues and their impact on tumorigenesis, as well as neutrophil-based therapeutic strategies that have shown promising results in pre-clinical studies, paving the way for the design of neutrophil-based next generation immunotherapy.

show abstract

Section: Circulating Neutrophils In Cancermentioning

confidence: 99%

Neutrophil Heterogeneity in Cancer: From Biology to Therapies

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Based on studies of the tumor microenvironment, the prognostic role of the NLR in PTCL has attracted more attention in recent years. On multivariate analysis in 59 patients with PTCLs for time to treatment failure (TTF), high NLR was extracted as adverse prognostic factors (HR = 2.25, 95% CI 1.23–4.10, P = 0.008) [ 28 ]. Zhao et al [ 29 ] conducted a retrospective study of 213 adult PTCL patients and assessed the prognostic role of the NLR in the CR and survival of PTCL patients, and univariable analysis indicated that the NLR was correlated with worse OS.…”

Section: Discussionmentioning

confidence: 99%

Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis

Liu

Zhang

et al. 2021

Cancer Cell Int

View full text Add to dashboard Cite

The neutrophil-to-lymphocyte ratio (NLR) as an inflammatory marker may represent changes between inflammation and host immunity that affect the prognosis of peripheral T-cell lymphoma (PTCL). To comprehensively evaluate the NLR in PTCL, we performed a meta-analysis to investigate the relationship between the NLR and overall survival (OS) and progression-free survival (PFS). PubMed, Embase, Cochrane library, and China National Knowledge Infrastructure (CNKI) were searched for all relevant studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were obtained from each study. Heterogeneity among the included studies was checked to determine whether fixed or random effects model was used. In total, 8 studies with 921 patients were included for the meta-analysis. High NLR significantly correlated with worse OS (HR = 2.20, 95% CI 1.71–2.83, P < 0.05) regardless of region (Asian or non-Asian), sample size (< 60 or ≥ 60), median age (< 60 or ≥ 60), disease type, or cut-off value (NLR < 3.9 or NLR ≥ 3.9). In terms of PFS, the NLR had no prognostic impact for patients with PTCL (HR = 1.12, 95% CI 0.57–2.20, P = 0.742). Our findings suggest that PTCL patients with high NLR are more likely to have worse OS compared to those with low NLR. Therefore, the NLR can serve as a prognostic marker in PTCL.

show abstract

“…Neutrophil count and LDH both routinely detected the hematological index and were easily available in our clinical practice. Previous studies have investigated the prognostic value of LDH level, neutrophil count, and NLR in many solid tumors (10,21,24). However, there was no investigation about the role of the LDH level combined with neutrophil count or NLR in the prognosis of ESCC patients treated with radiotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…However, the predictive value of neutrophil count in the prognosis of ESCC patients treated with radiotherapy is still unclear. Recently, the prognostic value of LDH has been widely investigated in various cancers, such as metastatic renal cell carcinoma (17), breast cancer (18), nasopharyngeal carcinoma (19), prostate cancer (20), lymphoma (21), non-small cell lung cancer (22), and ESCC (23,24). Although LDH and neutrophil count are reliable prognostic predictors, it is still not clear whether they can be combined together in a prognostic risk score model to predict the prognosis of ESCC patients treated with radiotherapy.…”

Section: Introductionmentioning

confidence: 99%

Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy

Luo

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: This present study aimed to explore the prognostic value of pretreatment neutrophil and lactate dehydrogenase (LDH) and to develop a prognostic risk scoring model to predict prognosis in esophageal squamous cell cancer (ESCC) patients treated with definitive radiotherapy. Methods: Retrospectively collected data of patients who received definitive radiotherapy for ESCC at Shantou Central Hospital between January 2009 and December 2015 were included for the analysis. The association between the level of LDH and neutrophil and clinicopathological characteristics were analyzed. We performed univariate and multivariate analyses to identify the prognostic predictors for patients with ESCC. Based on the results, we also developed a prognostic risk scoring model and assessed its predictive ability in the subgroups. Results: A total of 567 patients who received definitive radiotherapy for ESCC were included in the present study. The optimal cutoff values were 4.5 × 10 9 /L, 3.25, and 220 U/L for neutrophil, neutrophil-to-lymphocyte ratio (NLR), and LDH, respectively. A high level of LDH was significantly associated with advanced N stage (p = 0.031), and neutrophil count was significantly associated with gender (p = 0.001), T stage (p < 0.001), N stage (p = 0.019), clinical stage (p < 0.001), and NLR (p < 0.001). Multivariate survival analysis identified gender (p = 0.006), T stage (p < 0.001), N stage (p = 0.008), treatment modality (p < 0.001), LDH level (p = 0.012), and neutrophil count (p = 0.038) as independent prognostic factors for overall survival. Furthermore, a new prognostic risk scoring (PRS) model based on six prognostic factors was developed, in which the patients were divided into three groups with distinct prognosis (χ 2 = 67.94, p < 0.0001). Conclusions: Elevated baseline LDH level and neutrophil count predicted poor prognosis for ESCC patients treated with definitive radiotherapy. A PRS model comprised of LDH, neutrophil count, and other prognostic factors would help identify the patients who would benefit the most from definitive radiotherapy.

show abstract

A new prognostic score comprising lactate dehydrogenase, albumin and neutrophil to lymphocyte ratio to predict sensitivity to first-line chemotherapy in patients with peripheral T-cell lymphomas

Cited by 8 publications

References 35 publications

Neutrophil Heterogeneity in Cancer: From Biology to Therapies

Neutrophil Heterogeneity in Cancer: From Biology to Therapies

Prognostic significance of the neutrophil-to-lymphocyte ratio in peripheral T-cell lymphoma: a meta-analysis

Prognostic Significance of Baseline Neutrophil Count and Lactate Dehydrogenase Level in Patients With Esophageal Squamous Cell Cancer Treated With Radiotherapy

Contact Info

Product

Resources

About